Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Profit After Tax: 2018-2024

Historic Profit After Tax for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$257.6 million.

  • Allogene Therapeutics' Profit After Tax rose 37.55% to -$41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 88.09%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
  • Latest data reveals that Allogene Therapeutics reported Profit After Tax of -$257.6 million as of FY2024, which was up 21.29% from -$327.3 million recorded in FY2023.
  • Allogene Therapeutics' 5-year Profit After Tax high stood at -$182.1 million for FY2021, and its period low was -$340.4 million during FY2022.
  • Its 3-year average for Profit After Tax is -$308.4 million, with a median of -$327.3 million in 2023.
  • Per our database at Business Quant, Allogene Therapeutics' Profit After Tax soared by 42.46% in 2021 and then plummeted by 86.99% in 2022.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Profit After Tax stood at -$316.4 million in 2020, then surged by 42.46% to -$182.1 million in 2021, then plummeted by 86.99% to -$340.4 million in 2022, then rose by 3.86% to -$327.3 million in 2023, then climbed by 21.29% to -$257.6 million in 2024.